Fundamental Analysis of NEUROGENE INC(NASDAQ:NGNE) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NGNE. NGNE was compared to 564 industry peers in the Biotechnology industry. NGNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NGNE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

NGNE had negative earnings in the past year.

In the past year NGNE has reported a negative cash flow from operations.

NGNE had negative earnings in each of the past 5 years.

NGNE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NGNE has a better Return On Assets (-30.83%) than 66.31% of its industry peers.

NGNE's Return On Equity of -35.77% is fine compared to the rest of the industry. NGNE outperforms 74.69% of its industry peers.

		Industry Rank	Sector Rank
ROA	-30.83%
ROE	-35.77%
ROIC	N/A

ROA(3y)-34.38%

ROA(5y)-33.24%

ROE(3y)-41.01%

ROE(5y)-37.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGNE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, NGNE has more shares outstanding

Compared to 5 years ago, NGNE has more shares outstanding

Compared to 1 year ago, NGNE has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 12.32 indicates that NGNE is not in any danger for bankruptcy at the moment.

NGNE has a better Altman-Z score (12.32) than 87.34% of its industry peers.

NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

NGNE's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. NGNE outperforms 50.45% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	12.32

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.17 indicates that NGNE has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 12.17, NGNE belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.

NGNE has a Quick Ratio of 12.17. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.

NGNE's Quick ratio of 12.17 is amongst the best of the industry. NGNE outperforms 83.96% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.17
Quick Ratio	12.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.80% over the past year.

EPS 1Y (TTM)80.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-17.37%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 0.56% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y20.64%

EPS Next 2Y9.29%

EPS Next 3Y0.56%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGNE. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.29%

EPS Next 3Y0.56%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NGNE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (11/4/2024, 8:26:12 PM)

After market: 68.8599 +2.86 (+4.33%)

+19.93 (+43.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap857.34M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.83%
ROE	-35.77%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	12.17
Quick Ratio	12.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)80.8%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y20.64%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEUROGENE INC (NGNE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens